Evidence map›Paper›PMID 26286698›Full record

ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2016

Multiple sclerosis patients have a diminished serologic response to vitamin D supplementation compared to healthy controls.

Pavan Bhargava, Sonya U Steele, Emmanuelle Waubant, Nisha R Revirajan, Jacqueline Marcus, Marieme Dembele, Sandra D Cassard, Bruce W Hollis, Ciprian Crainiceanu, Ellen M Mowry

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 3 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 61 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Pavan BhargavaDepartment of Neurology, Johns Hopkins University, Baltimore, MD, USA.
Sonya U SteeleDepartment of Neurology, Johns Hopkins University, Baltimore, MD, USA.
Emmanuelle WaubantDepartment of Neurology, University of California San Francisco, San Francisco, CA, USA.
Nisha R RevirajanDepartment of Neurology, University of California San Francisco, San Francisco, CA, USA.
Jacqueline MarcusDepartment of Neurology, University of California San Francisco, San Francisco, CA, USA.
Marieme DembeleDepartment of Neurology, Johns Hopkins University, Baltimore, MD, USA.
Sandra D CassardDepartment of Neurology, Johns Hopkins University, Baltimore, MD, USA.
Bruce W HollisDepartment of Pediatrics, Medical University of South Carolina, Charleston, SC, USA.
Ciprian CrainiceanuDepartment of Biostatistics, Johns Hopkins School of Public Health, Baltimore, MD, USA.
Ellen M MowryDepartment of Neurology, Johns Hopkins University, Baltimore, MD, USA emowry1@jhmi.edu.
Johns Hopkins University · USUniversity of California, San Francisco · USMedical University of South Carolina · US

Funding

The effect of vitamin D on the clinical and imaging course of multiple sclerosisK23NS067055 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MOWRY, ELLEN M. · 2010 to 2014
$881k
NINDS NIH HHS K23 NS067055
6 · The paper itself

Abstract

backgroundVitamin D insufficiency is a risk factor for multiple sclerosis (MS), and patients do not always show the expected response to vitamin D supplementation.

objectiveWe aimed to determine if vitamin D supplementation leads to a similar increase in serum 25-hydroxyvitamin-D (25(OH)D) levels in patients with MS and healthy controls (HCs).

methodsParticipants in this open-label study were female, white, aged 18-60 years, had 25(OH)D levels ⩽ 75 nmol/l at screening, and had relapsing-remitting MS (RRMS) or were HCs. Participants received 5000 IU/day of vitamin D3 for 90 days. Utilizing generalized estimating equations we examined the relationship between the primary outcome (serum 25(OH)D level) and the primary (MS versus HC status) and secondary predictors.

resultsFor this study 27 MS patients and 30 HCs were enrolled. There was no significant difference in baseline 25(OH)D level or demographics except for higher body mass index (BMI) in the MS group (25.3 vs. 23.6 kg/m(2), p=0.035). In total, 24 MS subjects and 29 HCs completed the study. In a multivariate model accounting for BMI, medication adherence, and oral contraceptive use, MS patients had a 16.7 nmol/l (95%CI: 4.2, 29.2, p=0.008) lower increase in 25(OH)D levels compared with HCs.

conclusionsPatients with MS had a lower increase in 25(OH)D levels with supplementation, even after accounting for putative confounders.

Indexed as

AdultCholecalciferolDietary SupplementsFemaleHumansMiddle AgedMultiple Sclerosis, Relapsing-RemittingVitamin D25-hydroxyvitamin DCholecalciferolVitamin DMultiple sclerosisnutritionpharmacokineticsvitamin D supplementation

Identifiers

PMID26286698
PMCPMC4758937
OpenAlexW1502088983

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.